{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-033867","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.716639+00:00","generated_at":"2026-05-15T09:10:08.763740+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MaxCyte Q4 revenue $7.3M, down 16%; FY2025 revenue $33M; guides FY2026 $30-32M","bullets":["Q4 2025 total revenue $7.3M (-16% YoY); Core revenue $6.8M (-22% YoY). Net loss $9.6M.","FY2025 total revenue $33.0M (-15% YoY); Core revenue $29.6M (-9% YoY). Net loss $44.6M.","Cash and investments $155.6M at Dec 31, 2025, vs $190.3M a year earlier.","FY2026 guidance: total revenue $30-32M ($25-27M core, $5M SPL); expects cash ≥$136M.","Ended 2025 with 32 SPLs, 13 clinical programs in clinic, and one commercial program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-033867","json":"https://secwatch.observer/filing/0001104659-26-033867.json","markdown":"https://secwatch.observer/filing/0001104659-26-033867.md","text":"https://secwatch.observer/filing/0001104659-26-033867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000110465926033867/0001104659-26-033867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000110465926033867/mxct-20260324x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:10:08.763740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"618c7c189f9c05a3a7907cd014e6be924550c3db","claim":"MAXCYTE, INC. reported full year 2026 results: revenue Expects 2026 revenue of $30-32 million. Guidance initiated.","evidence_excerpt":"Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000110465926033867/0001104659-26-033867-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2026"},{"label":"Revenue","value":"Expects 2026 revenue of $30-32 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"79c2e70bacad79b1f394f61fbc14eea1ee38aa35","claim":"MAXCYTE, INC. reported fourth quarter ended December 31, 2025 results: revenue total revenue of $7.3 million, net income net loss was $9.6 million.","evidence_excerpt":"Total revenue for the fourth quarter of 2025 was $7.3 million, compared to $8.7 million in the fourth quarter of 2024, representing a decrease of 16%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000110465926033867/0001104659-26-033867-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2025"},{"label":"Revenue","value":"total revenue of $7.3 million"},{"label":"Net income","value":"net loss was $9.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}